StockNow
Log in
U.S. Markets

BioNTech (BNTX) ends its Phase 2 colorectal cancer clinical trial

StockNow breaking-news AI analysis

BioNTech completed enrollment in its Phase 2 colorectal cancer trial, which continues without modification following safety review, with final readouts projected for 2027.

1 stocks
BNTXBioNTech SE American Depositary Share$102.43Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Fed

Fed's Hammack (2026 voter, hawkish dissenter) says inflation will end the year around 3% and that it is currently not meeting target

Fed

Fed Chair Warsh says Fed has more work to do unless confident underlying inflation is moving towards 2% objective

Politics

US Trump Administration is reportedly working on AI rules to reduce China's remote access to chips, The Information reports citing sources